Future??? No worries!

[Anonymous]

This company's going down in a ball of flames.

 

[Anonymous]

Quarterly trips gone. Budgets slashed. No new products. Nonexistent training department. Ineffective leadership. Future looks bright! Bright as a supernova as it flames out! Prometheus living up to it's namesake.

 

[Anonymous]

Quarterly trips gone. Budgets slashed. No new products. Nonexistent training department. Ineffective leadership. Future looks bright! Bright as a supernova as it flames out! Prometheus living up to it's namesake.

Too much silicone in the training department and not enough product knowledge.

 

[Anonymous]

Why would Nestle expect anything other than ignorance? They allowed or forced the talent out the door. For such a successful company, it appears naïve. Rookie move, Nestle. Stick to cookies.

 

[Anonymous]

Why has Nestle' retained a Sales VP with no diagnostic sales experience? Smart play would be to ID and hire a senior VP from Quest or LabCorp. Do they want to succeed or are they looking for an exit statagy?

 

[Anonymous]

Why has Nestle' retained a Sales VP with no diagnostic sales experience? Smart play would be to ID and hire a senior VP from Quest or LabCorp. Do they want to succeed or are they looking for an exit statagy?

Dako is a diagnostic company!! Problem is no understanding of the US market, and the impact Obama care is having on the industry. Their is an attempt to cut diagnostic costs across the board.

 

[Anonymous]

Problem is AA clownsuit sillypants. Douch.

 

[Anonymous]

Obama is the issue. Much like was the case last night, when l spilled my pint gris. A funny thing happened on my way to this site... other Dx companies are thriving.

 

[Anonymous]

Dako sales to labs and diagnostic facilities. They do not market to MDs for specific patient testing. If this is wrong, why is the "experience of Dako" not translating into sales? Should not the Sales VP understand and react to Obama Care? The Dako link does explain the sorry nature of the training dept given AA's role in Dako training.

 

[Anonymous]

Why do you hate Alex so much? He is the executive mouth piece, some decision making ability, or able to pitch ideas, but very few final decisions are his. You are just killing the messanger.

 

[Anonymous]

Emminence front.. it's a put on. Nobody has even mentioned the negative comments hurled about regarding good people who have left the company, voluntarily or otherwise.

 

[Anonymous]

Why do you hate Alex so much? He is the executive mouth piece, some decision making ability, or able to pitch ideas, but very few final decisions are his. You are just killing the messanger.

"Executive mouth piece"? Really? VP of Sales is responsible to formulate and execute sales strategy. Alex plans trips and interrupts sales time with silly email question contests. You are either clueless or you are AA.

 

[Anonymous]

"Executive mouth piece". Really? Vice President of Sales is responsible for formulating and executing sales strategy. Alex plans quarterly trips and wastes rep sales time with silly mid-day email contests. Amazing! You are either clueless or you are Alex!

 

[Anonymous]

Quarterly trips gone. Budgets slashed. No new products. Nonexistent training department. Ineffective leadership. Future looks bright! Bright as a supernova as it flames out! Prometheus living up to it's namesake.

Again, this proliferation of negativity. From the calls today, you should be encouraged and revitalized that we have a plan to offset the loss of LTX volume - and that is to have a dedicated team of Proleukin beggars! Get out the kneepads and do those jaw exercises! #accelerated #lucky25 #teacherspetsorshouldisayasskissers

 

[Anonymous]

Prometheus continues success as contract pharm firm. Transferring 25 GI reps in part to oncology to sale proleukin. Six year agreement with Novartis signed 2010. Extension options then available yearly for up to six more years on annual basis. Is this job security? I bet the current onc reps are happy to share their narrow market drug and payout bonuses. Will the onc reps start saling GI testing? Must be a great day to be a GI diagnostics rep. Look for layoffs and retooled compensation. The bringer of fire continues to burn!

 

[Anonymous]

Prometheus continues success as contract pharm firm. Transferring 25 GI reps in part to oncology to sale proleukin. Six year agreement with Novartis signed 2010. Extension options then available yearly for up to six more years on annual basis. Is this job security? I bet the current onc reps are happy to share their narrow market drug and payout bonuses. Will the onc reps start saling GI testing? Must be a great day to be a GI diagnostics rep. Look for layoffs and retooled compensation. The bringer of fire continues to burn!

"sale proleukin"? "saling GI testing"? I hope and pray that you aren't representing us out in the field.

 

[Anonymous]

STANDARD TREATMENT — Metastatic melanoma –
High-dose interleukin-2 (aldesleukin – Proleukin) has produced responses in 15-20% of patients with metastatic melanoma, but its use has been limited by severe toxicity and cumbersome administration requiring hospitalization for treatment. The anti- CTLA4 monoclonal antibody ipilimumab (Yervoy) has produced response rates similar to those with high-dose interleukin-2, with 20-26% of patients surviving beyond 3 years.2,3 Recently, pembrolizumab has produced a higher response rate and longer progression-free and overall survival than ipilimumab.4 A panel of experts has recommended that pembrolizumab should be considered a first-line option for treatment of metastatic melanoma.5
June 2015 Medical Letter

To all you new onc reps, looks like your drug is soaring, off a cliff!

 

[Anonymous]

"sale proleukin"? "saling GI testing"? I hope and pray that you aren't representing us out in the field.

Why should I be in the field representing you Mr Spellcheck? Looking at sells, no one is. Better Alex?

 

[Anonymous]

STANDARD TREATMENT — Metastatic melanoma –
High-dose interleukin-2 (aldesleukin – Proleukin) has produced responses in 15-20% of patients with metastatic melanoma, but its use has been limited by severe toxicity and cumbersome administration requiring hospitalization for treatment. The anti- CTLA4 monoclonal antibody ipilimumab (Yervoy) has produced response rates similar to those with high-dose interleukin-2, with 20-26% of patients surviving beyond 3 years.2,3 Recently, pembrolizumab has produced a higher response rate and longer progression-free and overall survival than ipilimumab.4 A panel of experts has recommended that pembrolizumab should be considered a first-line option for treatment of metastatic melanoma.5
June 2015 Medical Letter

To all you new onc reps, looks like your drug is soaring, off a cliff!

You do realize they only have the hybrid reps promoting for renal cell carcinoma NOT metastatic melanoma right? But thanks for the info.

 

[Anonymous]

You do realize they only have the hybrid reps promoting for renal cell carcinoma NOT metastatic melanoma right? But thanks for the info.

Renal Cell Drugs

Sunitinib 50 mg/day PO for 28 d; every 6 wk (compared with interferon, it provides increased progression-free survival [PFS] and overall survival [OS]: PFS is 11mo with sunitinib vs 5 mo with interferon alone; median overall survival is 26.4 mo vs 21.8 mo with interferon alone, and response is 47% with sunitinib vs 12% with interferon alone)
emedicine.com

Oral vs IV, less toxic, more effective.

Your welcome. Hope the hybrids enjoy promoting an inferior drug. Any other questions Alex?